Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EARS

Auris Medical (EARS) Stock Price, News & Analysis

Auris Medical logo

About Auris Medical Stock (NASDAQ:EARS)

Advanced Chart

Key Stats

Today's Range
$0.30
$0.43
50-Day Range
$2.25
$3.27
52-Week Range
$0.73
$6.60
Volume
830,271 shs
Average Volume
3.10 million shs
Market Capitalization
$3.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Receive EARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.

EARS Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Headlines

EARS Stock Analysis - Frequently Asked Questions

Auris Medical Holding Ltd. (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $1.60.

Auris Medical's stock reverse split on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXDW), Novavax (NVAX), OPKO Health (OPK), Anavex Life Sciences (AVXL), Flexion Therapeutics (FLXN) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/11/2017
Today
5/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EARS
Fax
N/A
Employees
132,200
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.57 per share
Price / Book
0.19

Miscellaneous

Free Float
N/A
Market Cap
$3.43 million
Optionable
Not Optionable
Beta
1.17
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:EARS) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners